These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. Cosi C, Carilla-Durand E, Assié MB, Ormiere AM, Maraval M, Leduc N, Newman-Tancredi A. Eur J Pharmacol; 2006 Mar 27; 535(1-3):135-44. PubMed ID: 16554049 [Abstract] [Full Text] [Related]
6. Aripiprazole inhibits polyI:C-induced microglial activation possibly via TRPM7. Sato-Kasai M, Kato TA, Ohgidani M, Mizoguchi Y, Sagata N, Inamine S, Horikawa H, Hayakawa K, Shimokawa N, Kyuragi S, Seki Y, Monji A, Kanba S. Schizophr Res; 2016 Dec 27; 178(1-3):35-43. PubMed ID: 27614570 [Abstract] [Full Text] [Related]
7. Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation. Etievant A, Bétry C, Arnt J, Haddjeri N. Neurosci Lett; 2009 Aug 21; 460(1):82-6. PubMed ID: 19450663 [Abstract] [Full Text] [Related]
9. The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release. Aihara K, Shimada J, Miwa T, Tottori K, Burris KD, Yocca FD, Horie M, Kikuchi T. Brain Res; 2004 Apr 02; 1003(1-2):9-17. PubMed ID: 15019558 [Abstract] [Full Text] [Related]
11. Inhibitory effects of SSRIs on IFN-γ induced microglial activation through the regulation of intracellular calcium. Horikawa H, Kato TA, Mizoguchi Y, Monji A, Seki Y, Ohkuri T, Gotoh L, Yonaha M, Ueda T, Hashioka S, Kanba S. Prog Neuropsychopharmacol Biol Psychiatry; 2010 Oct 01; 34(7):1306-16. PubMed ID: 20654672 [Abstract] [Full Text] [Related]
13. Galantamine and nicotine have a synergistic effect on inhibition of microglial activation induced by HIV-1 gp120. Giunta B, Ehrhart J, Townsend K, Sun N, Vendrame M, Shytle D, Tan J, Fernandez F. Brain Res Bull; 2004 Aug 30; 64(2):165-70. PubMed ID: 15342104 [Abstract] [Full Text] [Related]
14. In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling. Jordan S, Regardie K, Johnson JL, Chen R, Kambayashi J, McQuade R, Kitagawa H, Tadori Y, Kikuchi T. J Psychopharmacol; 2007 Aug 30; 21(6):620-7. PubMed ID: 17092971 [Abstract] [Full Text] [Related]
16. Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Tadori Y, Forbes RA, McQuade RD, Kikuchi T. Eur J Pharmacol; 2009 Apr 01; 607(1-3):35-40. PubMed ID: 19217900 [Abstract] [Full Text] [Related]
17. Aripiprazole and haloperidol suppress excessive dopamine release in the amygdala in response to conditioned fear stress, but show contrasting effects on basal dopamine release in methamphetamine-sensitized rats. Oshibuchi H, Inada K, Sugawara H, Ishigooka J. Eur J Pharmacol; 2009 Aug 01; 615(1-3):83-90. PubMed ID: 19477171 [Abstract] [Full Text] [Related]
18. Partial agonist actions of aripiprazole and the candidate antipsychotics S33592, bifeprunox, N-desmethylclozapine and preclamol at dopamine D(2L) receptors are modified by co-transfection of D(3) receptors: potential role of heterodimer formation. Novi F, Millan MJ, Corsini GU, Maggio R. J Neurochem; 2007 Aug 01; 102(4):1410-24. PubMed ID: 17532788 [Abstract] [Full Text] [Related]
19. Antidepressants inhibit interferon-gamma-induced microglial production of IL-6 and nitric oxide. Hashioka S, Klegeris A, Monji A, Kato T, Sawada M, McGeer PL, Kanba S. Exp Neurol; 2007 Jul 01; 206(1):33-42. PubMed ID: 17481608 [Abstract] [Full Text] [Related]